Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TVGN
stocks logo

TVGN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Tevogen Bio Holdings Inc (TVGN.O) is -2.08, compared to its 5-year average forward P/E of -0.90. For a more detailed relative valuation and DCF analysis to assess Tevogen Bio Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.90
Current PE
-2.08
Overvalued PE
0.85
Undervalued PE
-2.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 140.46% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 140.46% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TVGN News & Events

Events Timeline

(ET)
2025-11-05
15:24:14
Tevogen Achieves Key Clinical Milestone in Development of ExacTcell Platform
select
2025-10-15 (ET)
2025-10-15
15:52:09
Tevogen Offers Update on TVGN 489 in Response to Interest from Long COVID Patients
select
2025-09-25 (ET)
2025-09-25
08:41:00
Tevogen Reports Major Advancements in the Development of the PredicTcell Platform
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-28Benzinga
Heartbeam Shares Surge Approximately 43%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Heartbeam Inc's Stock Surge: Heartbeam Inc's shares rose 43.3% in pre-market trading after announcing its regulatory strategy following the FDA's Not Substantially Equivalent decision on its Electrocardiogram Synthesis Software, with plans for an appeal or 510(k) resubmission.

  • Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including SMX PLC (+73.1%), Zenta Group (+26.7%), and Waton Financial (+21.1%), reflecting a positive trend in the market.

  • Major Losers: FBS Global Ltd experienced a sharp decline of 24.3%, while Tilray Brands fell 15% after announcing a reverse stock split, indicating volatility among certain stocks.

  • Market Overview: The pre-market trading session showed mixed results, with notable gains for some companies and significant losses for others, highlighting the fluctuating nature of the stock market.

[object Object]
Preview
9.5
11-04Newsfilter
Tevogen Addresses Financial Report, Emphasizing Robust Capital Efficiency and Minimal Cash Burn

  • Financial Clarity: Tevogen Bio Holdings Inc. plans to provide a reconciled set of non-GAAP metrics to clarify its financial position, particularly regarding its reported accumulated deficit of $129 million under U.S. GAAP standards.

  • Cash vs. Non-Cash Expenses: The company has raised under $42 million since its inception, with a total cash loss of approximately $41 million, while the remaining deficit largely consists of non-cash expenses amounting to about $88 million.

  • Investor Communication: Tevogen aims to enhance investor understanding by distinguishing between cash and non-cash components in its financial results, emphasizing transparency in its reporting.

  • Forward-Looking Statements: The press release includes forward-looking statements about Tevogen's growth and operational plans, highlighting potential risks and uncertainties that could impact future performance.

[object Object]
Preview
4.5
10-30Newsfilter
Tevogen Executives Connect with Business and Community Leaders to Showcase Recent Achievements

  • Tevogen's Biopharma Model: Tevogen Bio Holdings Inc. emphasizes its commitment to sustainability and affordability in precision medicine, aiming to make T cell therapies accessible for various diseases, including cancers and Long COVID.

  • Financial Projections: The company values its first clinical product, TVGN 489, at $9–$11 billion and estimates a potential top-line revenue of approximately $6.5 billion over five years for a product targeting liver cancer prevention.

  • AI Developments: Tevogen.AI has made significant progress in developing its PredicTcell™ model in collaboration with Microsoft and Databricks, which could lead to substantial cost savings in drug development.

  • Intellectual Property and Future Outlook: Tevogen has secured multiple patents related to its T cell therapies and AI technologies, while also acknowledging potential risks and uncertainties that could impact its growth and development plans.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tevogen Bio Holdings Inc (TVGN) stock price today?

The current price of TVGN is 0.4217 USD — it has decreased -1.4 % in the last trading day.

arrow icon

What is Tevogen Bio Holdings Inc (TVGN)'s business?

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.

arrow icon

What is the price predicton of TVGN Stock?

Wall Street analysts forecast TVGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVGN is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tevogen Bio Holdings Inc (TVGN)'s revenue for the last quarter?

Tevogen Bio Holdings Inc revenue for the last quarter amounts to -5.73M USD, decreased -5.85 % YoY.

arrow icon

What is Tevogen Bio Holdings Inc (TVGN)'s earnings per share (EPS) for the last quarter?

Tevogen Bio Holdings Inc. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Tevogen Bio Holdings Inc (TVGN)'s fundamentals?

The market is revising No Change the revenue expectations for Tevogen Bio Holdings Inc. (TVGN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -51.33%.
arrow icon

How many employees does Tevogen Bio Holdings Inc (TVGN). have?

Tevogen Bio Holdings Inc (TVGN) has 18 emplpoyees as of December 05 2025.

arrow icon

What is Tevogen Bio Holdings Inc (TVGN) market cap?

Today TVGN has the market capitalization of 83.79M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free